Sebastiano Emanuele Torrisi,1 Marlies Wijsenbeek,2 Leticia Orsatti,3 Manuel Quaresma,3 Birgit Schinzel,3 Michael Kreuter,4 Carlo Vancheri1
1Regional Referral Center for Rare Lung Diseases, University-Hospital “Policlinico G. Rodolico”, Catania, Italy; 2Department of Respiratory Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands; 3Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 4Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany
Introduction
- IPF is a progressive fibrosing interstitial lung disease (ILD) characterized by loss of lung function and early mortality.1
- Patients with IPF frequently have comorbidities that affect survival.2,3
- The TORVAN index and staging system was developed to predict mortality in patients with IPF based on age, FVC, DLco and common comorbidities.3